Abstract: A battery pack having a first cell unit and a second cell unit in which multiple battery cells are connected in series is provided. When the battery pack is not connected to an electric apparatus main body, the first cell unit and the second cell unit are in a non-connection state in which the first cell unit and the second cell unit are not electrically connected to each other. The battery pack includes: a microcomputer, connected to one of the first cell unit and the second cell unit; a residual quantity display portion, connected to the microcomputer and displaying a battery residual quantity of the battery pack; and a switch, being operated by a worker. When the switch is operated while in the non-connection state, the microcomputer is configured to perform a light-on control to display the battery residual quantity by the residual quantity display portion.

Abstract: A battery pack and an electric apparatus are provided. The battery pack is configured to be connectable to an electric apparatus main body of the electric apparatus. The battery pack includes: a first cell unit, including a first plurality of battery cells connected to each other, a first positive terminal, and a first negative terminal; a second cell unit, including a second plurality of battery cells connected to each other, a second positive terminal, and a second negative terminal; a microcomputer; and a casing, accommodating the first cell unit, the second cell unit, and the microcomputer. The first cell unit and the second cell unit are configured to be switched a connection state each other. The microcomputer is configured to be electrically connected to a positive terminal and a negative terminal of one of the first cell unit and the second cell unit and to be provided a power from the one of the first cell unit and the second cell unit.

Abstract: An object of the present invention is to provide a pharmaceutical agent useful for treating and preventing neurological disease, having satisfactory solubility and oxidative stress-mediated cell death suppressive activity as well as capable of exhibiting excellent blood-brain barrier permeability. The present invention is directed to an acylaminoimidazole derivative represented by general formula (I) or a salt thereof, and a pharmaceutical and a therapeutic or preventive agent for neurological disease containing the same, as an active ingredient.

Abstract: An object of the present invention is to provide a pharmaceutical agent useful for treating and preventing neurological disease, having satisfactory solubility and oxidative stress-mediated cell death suppressive activity as well as capable of exhibiting excellent blood-brain barrier permeability. The present invention is directed to an acylaminoimidazole derivative represented by general formula (I) or a salt thereof, and a pharmaceutical and a therapeutic or preventive agent for neurological disease containing the same, as an active ingredient.

Abstract: A rice anthranilic acid synthase produced by introducing a variation in the base sequence of rice anthranilic acid synthase gene OASA2 so as to effect substitution for specified multiple amino acids. This synthase not only acquires a resistance to feedback inhibition by tryptophan but also retains an enzymatic activity identical with or higher than that of wild type rice anthranilic acid synthase.